Effects of torcetrapib in patients at high risk for coronary events.

By P. Barter, M. Caulfield, M. Eriksson, S. Grundy, J. Kastelein, M. Komajda, J. López-Sendón, L. Mosca, J. Tardif, D. Waters and 6 more. New England Journal of Medicine, 2007

2,926 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/49cf7a36699bfe7bf3d760ce32fe30bf87be526c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

In Endocrinology, Diabetes and Metabolism

In Surgery

Citations in the corpus

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management (2011, result): “Despite this, the first outcome study with torcetrapib, ILLUMINATE, was prematurely terminated due to excess mortality.(230) However, recent evidence(231,232) suggests that off-target pharmacological effects of torcetrapib were responsible for this adverse outcome rather than a”
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, background): “Of the three CETP inhibitors developed originally (torcetrapib, dalcetrapib and anacetrapib), torcetrapib was withdrawn following an excess of mortality in the torcetrapib arm of the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.(294) T”
Lipoprotein Management in Patients With Cardiometabolic Risk (2008, result): “Because a recent trial with a cholesteryl ester transfer protein inhibitor to raise HDL cholesterol was terminated as a result of excess cardiovascular events, it remains unclear whether raising HDL cholesterol per se reduces cardiovascular risk (91).”
HIGH BLOOD PRESSURE AND CARDIOVASCULAR DISEASE (2019, background): “Examples come from studies using celecoxib,(46) sibutramine,(47) and torcetrapib.(48) In contrast, prevention of”
Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. (2016, positive): “A necessity for triglyceride-rich lipoproteins to cause atherosclerosis and ASCVD is their ability to enter into the arterial intima, the location of the atherosclerotic plaque, leading ultimately to ASCVD.”
Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. (2014, background): “fer protein inhibitors will enhance cardiovascular outcomes has been tested in 2 clinical trials.(83,84) The Investigation of Lipid”
The Emerging Paradigm of Network Medicine in the Study of Human Disease (2012, background): “102,103 Based on in silico predictions of protein-ligand binding, Xie et al identified a panel of off-targets for torcetrapib and other CETP inhibitors from the human structural genome and mapped those targets to a network of biological pathways curated from the literature.”